This CME activity is provided by Integrity Continuing Education, Inc.
Supported by independent educational grants from Eisai, GlaxoSmithKline, and Merck Sharp & Dohme Corp.
Endometrial cancer (EC) is the most common gynecologic malignancy in the United States. Recent unraveling of the molecular profile of EC and its tumor microenvironment has revealed the immunologic nature of this diseases, showing that up to 91% of patients with advanced or recurrent EC have at least one genetic mutation that can serve as an actionable therapeutic target.
Immune checkpoint inhibitors (ICIs) are being researched as both monotherapy and in synergistic combinations with cytotoxic, hormonal, and targeted treatments for greater efficacy and improved survival outcomes for patients with EC. Although sometimes almost miraculously effective at eradicating tumors and ensuring long duration of response, ICIs can cause treatment-related adverse events (TRAEs) that clinicians aren’t expecting and that are unlike the adverse events (AEs) caused by more traditional therapies. This is even more pronounced when using combination strategies. These TRAEs can have a significant impact on patient quality of life (QOL). This Twitter Chat will include live discussion of these topics by top gynecologic oncology experts.
Don S. Dizon, MD, FACP, FASCO
Professor of Medicine
Director, Women’s Cancers and Hematology-Oncology Outpatient Clinics
Lifespan Cancer Institute
Director, Medical Oncology & Oncology Sexual Health Program
Rhode Island Hospital
Providence, Rhode Island
Amir A. Jazaeri, MD
Vice Chair, Clinical Research
Director, Gynecologic Cancer Immunotherapy Program
Professor, Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Martina Murphy, MD (Co-Chair)
Assistant Professor of Medicine
Director, Introduction to Clinical Medicine 1 & 2
Program Director, Hematology/Oncology Fellowship
University of Florida
This program is intended for medical oncologists, gynecologic oncologists, primary care physicians, advanced practice providers, emergency department physicians, and pharmacists involved in the management and treatment of patients with EC.
Upon completion of this educational activity, participants should be able to:
There are no fees for participating and receiving CME credit for this activity. During the period of January 27, 2021 through January 27, 2022, participants must:
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Live Participation on January 27, 2021:
Integrity Continuing Education, Inc. designates this live program for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participation from January 28, 2021 – January 27, 2022:
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or email@example.com.
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Don S. Dizon, MD, FACP, FASCO
Consulting Fees: Astra Zeneca, Clovis, Regeneron
Contracted Research: Bristol-Myers Squibb, Kazia, Pfizer, Tesaro (Institutional funds)
Amir A. Jazaeri, MD
Consulting Fees: Gerson Lehrman Group, Guidepoint
Contracted Research: Aravive, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Genentech, Iovance, Merck
Other (Scientific Advisory Boards): Avenge Bio, Nuprobe, TwoXar
Other (Ad hoc Advisory Boards): Eisai, Genentech-Roche, Iovance, Simcere
Martina Murphy, MD has no real or apparent conflicts of interest to disclose.
The Integrity Continuing Education, Inc. planners/managers have nothing to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)
Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer below 8 is not recommended.
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.